Samsung, Sandoz sign deal to commercialize biosimilar SB17

Samsung Bioepis headquarters in Songdo, Incheon [SAMSUNG BIOEPIS]

Samsung Bioepis signed an agreement with Switzerland’s Sandoz for the sales of its Stelara biosimilar drug in the North American and European regions.

Samsung Bioepis’ SB17, a proposed biosimilar to Janssen Pharmaceuticals’ blockbuster psoriasis treatment Stelara, is the Incheon-based biopharmaceutical company’s fourth biosimilar candidate in the immunology pipeline.

Celltrion reaches patent agreement for Stelara biosimilar CT-P43

In March, the company presented its Phase 1 clinical study results for SB17. Phase 3 was completed in December last year.

Stelara is the brand name for the ustekinumab drug. The global ustekinumab market size reached $17.7 billion in 2022, according to market tracker Iqvia.

BY SHIN HA-NEE [shin.hanee@joongang.co.kr]